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STUDY QUESTION: Does experimental manipulation of fibroblast growth factor 9 (FGF9)-signalling in human fetal gonads alter sex-specific
gonadal differentiation?
SUMMARY ANSWER: Inhibition of FGFR signalling following SU5402 treatment impaired germ cell survival in both sexes and severely
altered the developing somatic niche in testes, while stimulation of FGF9 signalling promoted Sertoli cell proliferation in testes and inhibited
meiotic entry of germ cells in ovaries.
WHAT IS KNOWN ALREADY: Sex-specific differentiation of bipotential gonads involves a complex signalling cascade that includes a
combination of factors promoting either testicular or ovarian differentiation and inhibition of the opposing pathway. In mice, FGF9/FGFR2
signalling has been shown to promote testicular differentiation and antagonize the female developmental pathway through inhibition of WNT4.
STUDY DESIGN, SIZE, DURATION: FGF signalling was manipulated in human fetal gonads in an established ex vivo culture model by
treatments with recombinant FGF9 (25 ng/ml) and the tyrosine kinase inhibitor SU5402 (10 μM) that was used to inhibit FGFR signalling.
Human fetal testis and ovary tissues were cultured for 14 days and effects on gonadal development and expression of cell lineage markers were
determined.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Gonadal tissues from 44 male and 33 female embryos/fetuses from first
trimester were used for ex vivo culture experiments. Tissues were analyzed by evaluation of histology and immunohistochemical analysis of
markers for germ cells, somatic cells, proliferation and apoptosis. Culture media were collected throughout the experimental period and pro-
duction of steroid hormone metabolites was analyzed in media from fetal testis cultures by liquid chromatography–tandem mass spectrometry
(LC-MS/MS).
MAIN RESULTS AND THE ROLE OF CHANCE: Treatment with SU5402 resulted in near complete loss of gonocytes (224 vs. 14 OCT4+
cells per mm2, P < 0.05) and oogonia (1456 vs. 28 OCT4+ cells per mm2, P < 0.001) in human fetal testes and ovaries, respectively. This was
a result of both increased apoptosis and reduced proliferation in the germ cells. Addition of exogenous FGF9 to the culture media resulted
in a reduced number of germ cells entering meiosis in fetal ovaries (102 vs. 60 γ H2AX+ germ cells per mm2, P < 0.05), while in fetal testes
FGF9 stimulation resulted in an increased number of Sertoli cells (2503 vs. 3872 SOX9+ cells per mm2, P < 0.05). In fetal testes, inhibition
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SOX9-positive Sertoli cells (2503 vs. 1561 SOX9+ cells per mm2, P < 0.05). In interstitial cells, reduced expression of COUP-TFII and increased
expression of CYP11A1 and CYP17A1 in fetal Leydig cells was observed, although there were no subsequent changes in steroidogenesis.
LARGE SCALE DATA: N/A
LIMITATIONS, REASONS FOR CAUTION: Ex vivo culture may not replicate all aspects of fetal gonadal development and function in vivo.
Although the effects of FGF9 were studied in ex vivo culture experiments, there is no direct evidence that FGF9 acts in vivo during human fetal
gonadogenesis. The FGFR inhibitor (SU5402) used in this study is not specific to FGFR2 but inhibits all FGF receptors and off-target effects on
unrelated tyrosine kinases should be considered.
WIDER IMPLICATIONS OF THE FINDINGS: The findings of this study suggest that dysregulation of FGFR-mediated signalling may affect
both testicular and ovarian development, in particular impacting the fetal germ cell populations in both sexes.
STUDY FUNDING/COMPETING INTEREST(S): This work was supported in part by an ESPE Research Fellowship, sponsored by Novo
Nordisk A/S to A.JØ. Additional funding was obtained from the Erichsen Family Fund (A.JØ.), the Aase and Ejnar Danielsens Fund (A.JØ.),
the Danish Government’s support for the EDMaRC programme (A.JU.) and a Wellcome Trust Intermediate Clinical Fellowship (R.T.M.,
Grant no. 098522). The Medical Research Council (MRC) Centre for Reproductive Health (R.T.M.) is supported by an MRC Centre Grant
(MR/N022556/1). The authors have no conflict of interest to disclose.
Key words: human fetal testis / human fetal ovary / ex vivo culture / FGF9 signalling / gonocytes / oogonia / gonadal sex differentiation
/ initiation of meiosis / somatic niche formation
Introduction
Development of ovaries or testes from a bipotential fetal gonad is a
fundamental aspect of embryogenesis. This sex-specific differentiation
involves a complex signalling cascade that directs gonad development
based on cues from the somatic niche, resulting ultimately in the
development of testes or ovaries (reviewed in Rotgers et al., 2018).
Testicular differentiation is triggered by expression of SRY in pre-Sertoli
cells, which in human fetal development is initiated from around 5–
6 gestational weeks (GWs) (Berta et al., 1990; Sinclair et al., 1990).
Subsequently, SRY triggers the expression of SOX9 and other male-
promoting factors including FGF9 and PGD2 (Hanley et al., 2000;
Ostrer et al., 2007), which have so far mainly been characterized in
mice. Together, these factors promote early events relating to normal
testis development, including regulation of somatic cell lineage differ-
entiation and commitment of germ cells to the male developmental
program, as well as inhibition of female pathway factors (reviewed
in Windley and Wilhelm, 2015; Rotgers et al., 2018; Mäkelä et al.,
2018). In humans, the initial testicular differentiation is distinguish-
able from 7–8 GWs when the gonocytes become surrounded by
Sertoli cells and are enclosed within the forming seminiferous cords
(Ostrer et al., 2007). At this stage, the fetal testis undergoes sub-
stantial reorganization directed by chemotactic signals produced by
the Sertoli cells to establish the seminiferous cords and the interstitial
compartment. The somatic niche ensures optimal support of the fetal
gonocytes, which at this developmental time point are proliferating
and actively prevented from prematurely entering meiosis (reviewed
in Jørgensen and Rajpert-De Meyts, 2014). Human fetal gonocytes
are characterized by expression of pluripotency markers, which are
expressed until the gonocytes differentiate to pre-spermatogonia in an
asynchronous manner starting towards the end of the first trimester
(Mitchell et al., 2008).
Organogenesis of the fetal ovary is less well understood, especially
in humans, but upon initiation of ovarian differentiation, expression
of WNT4/RSPO1/β-catenin is stabilized. In human fetal gonads,















































































fluctuation, whereas RSPO1 expression is ovary-specific (Tomaseli
et al., 2011; Mamsen et al., 2017). Following initiation of the female
fate by the WNT4/RSPO1/β-catenin pathway, granulosa cell fate is
enforced by expression of FOXL2 (Ottolenghi et al., 2005; Uhlenhaut
et al., 2009), which is distinguishable from around GW 8 in human
ovaries (Jørgensen et al., 2015). The interstitial cell population in human
fetal ovaries is characterized by expression of COUP-TFII with no
co-expression between FOXL2-positive granulosa cells and COUP-
TFII-positive stromal cells (Bashamboo et al., 2018). The oogonia are
highly proliferative during first trimester and already at GW 9 there
are approximately eight times more oogonia present in the ovaries
compared to gonocytes in the testes (Bendsen et al., 2003; Bendsen
et al., 2006). Another key event in early fetal ovary development is
the initiation of meiosis, which starts from around 10–12 GWs in the
human ovary and continues in an asynchronous manner, resulting in
simultaneous presence of proliferating oogonia located in the periph-
ery of the ovary and meiotic oocytes present deeper within the medulla
(Anderson et al., 2007; Frydman et al., 2017). The initiation of meiosis
is at least in part triggered by retinoic acid (Le Bouffant et al., 2010;
Jørgensen et al., 2015), which stimulates the upregulation of the pre-
meiosis marker STRA8 and subsequently the meiotic signalling cascade
that includes SCP3, SPO11 and DMC1, coinciding with downregulation
of pluripotency factor expression (Houmard et al., 2009; Le Bouffant
et al., 2010; Childs et al., 2011; Jørgensen et al., 2012; Gkountela et al.,
2013).
In mice, FGF9/FGFR2 is an important signalling pathway in the
promotion of testis development that is activated just downstream of
SRY and SOX9. Deletion of either FGF9 or FGFR2 in mice results in
male-to-female sex reversal (Colvin et al., 2001; DiNapoli et al., 2006;
Kim et al., 2007). Sex reversal has also been reported in a 46,XY patient
with a FGFR2 mutation (Bagheri-Fam et al., 2015). The similar gonadal
phenotype in knock-out (KO) models of FGF9 and FGFR2 suggests that
FGF9 mediates its effects through the FGFR2 receptor during fetal testis
development. Interestingly, in addition to its initially described role in
promoting the male pathway, FGF9/FGFR2 signalling suppresses Wnt4
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in Fgf9–/– fetal testes (Kim et al., 2006). Accordingly, more recent results
from double KO models (Fgf9/Wnt4 and Fgfr2/Wnt4) suggest that the
primary role of FGF9/FGFR2 signalling in fetal testis development is to
ensure repression of the ovary-promoting gene Wnt4 (Jameson et al.,
2012). However, FGF9/FGFR2 signalling in mice is also involved in
germ cell survival in fetal testes (DiNapoli et al., 2006), as well as in the
promotion of male pathway genes and inhibition of meiotic initiation
in mouse fetal gonads (Barrios et al., 2010; Bowles et al., 2010; Gustin
et al., 2016). Interestingly, a recent study demonstrated that FGF9
signalling is active in human fetal ovaries and that FGF9 plays a role
in the prevention of meiotic entry (Frydman et al., 2017). However,
the role of FGF9/FGFR2 signalling in human fetal gonad development,
especially in the testis, has not yet been characterized in detail. There-
fore, the present study aimed to investigate the role of FGF9 signalling
in both human fetal testis and ovary development by stimulating FGF9
signalling and inhibiting FGFR signalling in an established ex vivo culture
model.
Materials and Methods
Collection of human fetal gonads and ethical
approval
Human fetal gonads were isolated from material available follow-
ing elective termination of pregnancy during the first trimester at
the Department of Gynaecology at Copenhagen University Hospital
(Rigshospitalet) and Hvidovre Hospital, Denmark. The regional ethics
committee approved this study (permit number H-1-2012-007, includ-
ing amendments 48801, 50662, 55184 and 64377) and women gave
their informed written and oral consent. None of the terminations
were for reasons of pathology of pregnancy or fetal abnormality.
The embryos/fetuses included in this study were between 7 and 12
GWs, with fetal age determined by scanning crown-rump length and
by evaluation of foot length (Evtouchenko et al., 1996). The fetuses
were dissected in ice cold PBS and the isolated fetal gonads were
immediately set up in ex vivo cultures. Gonad tissue from 44 male
and 33 female fetuses was used for the ex vivo culture experiments
followed by formalin fixation. Moreover, 12 fetal testis and 14 fetal
ovary samples were immediately snap-frozen and stored at −80◦C
until further analysis by qRT-PCR. In total, this corresponded to 103
gonadal tissue samples. Some of the samples used for qRT-PCR analysis
have also been used for gene expression analysis in a previous study
(Jørgensen et al., 2018).
Ex vivo gonad tissue culture
Human fetal gonads were cultured ex vivo in hanging drops as described
previously (Jørgensen et al. 2015, 2018), with a few modifications. All
gonads were initially divided into ∼1 mm3 fragments prior to culture
set up with at least one piece from each embryo/fetus used as vehicle
control. The tissue was cultured in 40 μl medium for 14 days. Medium
composition was: MEMα medium supplemented with 1× MEM non-
essential amino acids, 2 mM sodium pyruvate, 2 mM L-glutamine, 1 ×
insulin, transferrin and selenium (ITS) supplement, (Sigma-Aldrich), 1
× penicillin/streptomycin, 10% fetal bovine serum. All cell media and
supplements were from Gibco (Nærum, Denmark), except ITS (Sigma-
Aldrich, Brøndby, Denmark). Fragments of gonads were cultured at





























































































































from each tissue fragment was collected and pooled throughout the
experimental period. To manipulate FGF signalling, fetal gonads were
cultured in medium containing either 25 ng/ml recombinant human
FGF9 (Sigma # SRP3040) or 10 μM SU5402 (FGFR tyrosine kinase
inhibitor, Calbiochem #572630). FGF9 was dissolved in PBS with 0.1%
BSA and SU5402 was dissolved in dimethyl sulfoxide vehicle (DMSO,
0.1%) (Sigma-Aldrich).
Quantitative RT-PCR
Quantitative RT-PCR was conducted using the Mx300P platform
(Stratagene, Cedar Creek, TX, USA), as previously described
(Jørgensen et al., 2018). In brief, total RNA was extracted from frozen
specimens and isolated with NucleoSpin RNA II purification kit, as
described by the manufacturer (Macherey-Nagel, Düren, Germany).
cDNA was synthesized using a dT20 primer and random hexamers.
Gene expression was examined using specific primers (Table I) that
were designed to span intron-exon boundaries and all amplicons
were sequenced to verify specificity of primers (Eurofins Genomics,
Ebersberg, Germany). Standard curve analysis and efficiency of
amplification was established for all primers. Quantitative RT-PCR
analysis was measured in technical triplicates using Stratagene Mx300P
system with SYBR Green QPCR Master Mix (Stratagene, La Jolla, USA).
PCR conditions were: 95◦C 1 min + (95◦C 30 s + 60◦C 1 min + 72◦C
1 min) × 40 + 95◦C 1 min + 55◦C 30 s + 95◦C 30 s. Changes in gene
expression were quantified using the 2−Ct method. Expression levels
were normalized to RPS29 expression and calculated as a ratio relative
to testis samples from 7–9 GWs, which were set to 1.
Immunohistochemistry
Gonadal tissue was fixed in formalin immediately after the end
of the ex vivo culture period. The fixed gonads were dehydrated,
paraffin-embedded and sectioned (4 μm) using standard procedures.
Immunohistochemistry (IHC) was conducted as previously described
for formalin-fixed samples (Jørgensen et al., 2012). In brief, antigen
retrieval was accomplished by microwaving the sections for 15 min in
retrieval buffer. Sections were then incubated with 2% non-immune
goat serum (Zymed Histostain kit, San Francisco, CA, USA) or 0.5%
milk powder diluted in tris buffered saline (TBS) to minimize cross-
reactivity. Primary antibodies, dilutions and retrieval buffers are listed in
Table II. After 16 h of incubation at 4oC and 1 h at room temperature,
the sections were incubated with biotinylated goat anti-rabbit IgG
(Zymed Histostain kit) or biotinylated goat anti-mouse IgG, before a
peroxidase-conjugated streptavidin complex (Zymed Histostain kit)
was used as a tertiary layer. Visualisation was performed with amino
ethyl carbasole (AEC) (NOVEX) yielding a red colour and sections
were counterstained with Mayer’s haematoxylin. For all antibodies
used, a positive control sample (tissue/cells known to express the
studied protein) was included in the optimization of the antibody
(Table II). Additionally, negative controls were included and processed
with the primary antibody replaced by the dilution buffer alone. None
of the negative control sections showed staining.
Immunofluorescence
Immunofluorescence (IF) was conducted as described in detail
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Table I Primer sequences.
Gene Forward primer 5′-3′ Reverse primer 5′-3′ Amplicon size GenBank Accession no.
.......................................................................................................................................................................................
FGF9 CTACCTCGGGATGAATGAGAA TTTCTGGTGCCGTTTAGTCCT 208 bp NM_002010
FGFR2 GGCTTCCAGTCAAGTGGAT TTCGTTGGTGCAGTTGGCT 203 bp NM_000141
OCT4 (POU5F1) TACTCCTCGGTCCCTTTCC CAAAAACCCTGGCACAAACT 166 bp NM_002701
NR2F2 TCCTGTTCACCTCAGATGCC CTTTCCGAATCTCGTCGGCT 131 bp NM_021005
SOX9 AGTACCCGCACTTGCACAAC TCTCGCTCTCGTTCAGAAGTCT 75 bp NM_000346
CYP17A1 GAGTTTGCTGTGGACAAGGG CGCTGGATTCAAGAAACGCT 117 bp NM_000102
RPS29 CGCTCTTGTCGTGTCTGTTCA CCTTCGCGTACTGACGGAAA 91 bp NM_001032
Table II Antibody dilutions, retrieval buffer and details.
Antibody Dilution Retrieval buffer Company Cat. Number Positive control (tissue, cell type)
.......................................................................................................................................................................................
OCT4 1:50 TEG Santa Cruz Sc-5279 Adult testis, GCNIS cells
NANOG 1:50 Citrate R&D Systems AF-1997 Adult testis, GCNIS cells
AP2γ 1:50 Urea Santa Cruz Sc-12762 Adult testis, GCNIS cells
MAGE-A4 1:250 TEG Non-commercial Gift from Prof. Spagnoli Adult testis, Spermatogonia
AMH 1:400 Citrate Santa Cruz Sc-6886 Fetal testis, Sertoli cells
SOX9 1:400 Citrate Millipore AB5535 Adult testis, Sertoli cells
cPARP 1:75 Citrate Cell Signaling 5625 Adult testis, nuclease treated
BrdU 1:100 Citrate Dako M0744 Adult testis culture, BrdU-treated
COUP-TFII 1:50 Citrate Perseus Proteomics PP-H7147-60 Adult testis, Interstitial cells
CYP11A1 1:250 TEG Sigma HPA016436 Adult testis, Leydig cells
CYP17A1 1:200 Citrate Abcam Ab134910 Adult testis, Leydig cells
3β-HSD 1:6000 Citrate Non-commercial Gift from Prof. Mason Adult testis, Leydig cells
γ H2AX 1:800 TEG Abcam Ab26350 Adult testis, Spermatocytes
SCP3 1:800 TEG Novus NB300-232 Adult testis, Spermatocytes
FOXL2 1:75 Citrate Non-commercial Gift from Dr. Wilhelm Fetal ovary, Granulosa cells
WNT4 1:200 Citrate Abcam Ab-91226 Fetal ovary, Granulosa cells
FGF9 1:100 Citrate Santa Cruz Sc-7876 Fetal testis, Germ cells and Sertoli cells∗
For all antibodies, antigen retrieval was conducted by microwaving sections in the indicated retrieval buffer. Citrate buffer: 10 mM, pH 6.0; TEG buffer: 10 mM Tris, 0.5 mM EGTA, pH
9.0; Urea buffer: 5% w/v carbamide, pH 5.5. ∗As previously reported by Ostrer et al. (2007) using the same antibody.
dewaxed and rehydrated using standard procedures, followed by
heat-induced antigen retrieval (pressure cooker) in 0.01 M citrate
buffer (pH 6) and subsequent peroxidase block in 3% (v/v) H2O2
in methanol for 30 min. Sections were blocked in normal chicken
serum (NCS; Biosera, Ringmer, UK) diluted 1:5 in TBS containing
5% (w/v) BSA. The primary antibodies OCT4 (Santa Cruz, sc-5279)
and FGF9 (Santa Cruz, sc-7876) were both diluted 1:100, while
secondary peroxidase-conjugated chicken anti-mouse and chicken anti-
rabbit, respectively, were diluted 1:200. Following incubation with the
appropriate secondary antibody, slides were incubated with Tyr-Cy3
and Tyr-Fluorescein (Perkin Elmer-TSA-Plus Cyanine3 System; Perkin
Elmer Life Sciences, Boston, MA, USA) according to the manufacturer’s
instructions. Sections were counterstained with DAPI (Sigma) diluted
1:500 in TBS for 10 min. Finally, slides were mounted with Permafluor
(Thermo Scientific, UK) and fluorescent images were captured using





































BrdU incorporation was used to determine the presence of prolifer-
ating germ cells just prior to the end of the ex vivo culture period, as
previously described (Jørgensen et al., 2014). In brief, BrdU-labelling
reagent (Life Technologies, Nærum, Denmark) was diluted 1:100 in
culture medium and tissue fragments were placed in BrdU-containing
media for 6 h. Tissue pieces were then washed twice in PBS for
5 min each, followed by fixation and paraffin embedding as described
above. BrdU was visualized by IHC using a BrdU antibody (Table II)
as described in the IHC section, with the positively stained cells
considered as proliferating.
Quantification of stained cells
To evaluate the IHC staining, the number of stained cells was quantified
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Table III LC-MS/MS validation parameters for androgens and corticosteroids in cell media from fetal testis cultures.
Control Low Control High
................................................. .............................................
LOQ Range mean RSD recovery mean RSD recovery
(nM) (nM) (nM) (%) (%) (nM) (%) (%)
.......................................................................................................................................................................................
Estrone 1-sulfate 0.026 LOQ-10 0.50 21.7 101 2.77 5.2 92
Cortisone 0.19 LOQ-112 1.90 5.5 95 23.4 4.8 94
Cortisol 1.9 LOQ-794 10.0 4.2 100 154 2.2 103
Dehydroepiandrosterone sulphate 19 LOQ-3000 48.3 8.8 97 614 8.7 102
Corticosterone 0.1 LOQ-144 1.99 4.3 100 28.7 3.3 96
11-deoxycortisol 0.017 LOQ-40 1.03 4.2 103 20.7 2.8 103
4-androstenedione 0.042 LOQ-1746 19.1 3.1 95 285 2.5 95
Testosterone 0.012 LOQ-1732 9.69 4.4 97 724 2.5 97
17α-hydroxyprogesterone 0.1 LOQ-1513 26.3 4.5 105 438 3.8 109
Progesterone 0.036 LOQ-500 5.54 4.7 111 112 4.3 112
Limits of quantification (LOQ), range of calibration curves based on 10 standards and results of inter-day control materials (n = 32) at low and high levels from 11 batches. RSD: relative
standard deviation.
lated using the NDPview software (Hamamatsu Photonics, Herrsching
am Ammersee, Germany). Gonocytes and oogonia were identified
based on OCT4 staining; proliferating cells were identified by BrdU
incorporation; apoptotic cells were identified by cPARP staining; mei-
otic germ cells were identified by γ H2AX staining (detects double-
strand breaks and therefore potentially also apoptotic cells); and Sertoli
cells were identified by SOX9 staining. For all quantifications, tissue
samples from at least six embryos/fetuses were included.
Steroid hormone measurements
by LC-MS/MS
Steroid hormone levels in culture media following ex vivo culture
were measured as described previously (Jørgensen et al., 2018).
In brief, a sensitive isotope dilution TurboFlow-LC-MS/MS method
was used for simultaneous quantification of dehydroepiandros-
terone sulfate (DHEAS), 4-androstenedione, testosterone, 17α-
hydroxyprogesterone, progesterone, 11-deoxycortisol, cortisol,
cortisone, corticosterone and estrone 1-sulfate (E1-S) (Søeborg et al.,
2017). The following modifications were applied: calibration curves
were prepared in culture media; control samples were prepared by
spiking with high and low concentration of steroids; and all collected
media samples were diluted four times in culture media prior to
analysis. A few samples were re-analysed for testosterone after
additional sample dilution. Samples were analysed in 11 batches
during summer/autumn of 2016. Each batch included standards for
calibration curves, ∼20 unknown samples, one blank and three pooled
controls spiked with steroid standards at low and high levels. The day-
to-day variation expressed as the relative standard deviation (RSD)
was ≤6% for all analytes in both spike levels except for E1-S in a low
spike level (22%). The recovery was >92% for all analytes in both spike
levels. Additional details are listed in Table III.
Statistical analysis
Statistical analysis was performed using GraphPad Prism Software.












































































dent’s paired (two-tailed) t-test was used. If samples were not paired,
Student’s unpaired (two-tailed) t-test was used. Asterisks indicate
statistical significance with ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. The
number of replicates in each experimental setting and statistical sig-
nificance are specified in each figure legend.
Results
Expression of FGF9 and FGFR2 in human
fetal testes and ovaries
To establish the presence of FGF9 and FGFR2 expression in human fetal
testis and ovary samples during the first trimester, the transcriptional
expression levels of FGF9 and FGFR2 were examined together with
selected cell lineage markers POU5F1 (OCT4), NR2F2 (COUP-TFII),
SOX9 and CYP17A1 (Fig. 1A). FGF9 and FGFR2 were expressed at
similar levels in testis and ovary samples, but with a significant (P < 0.05)
increase in the expression level of FGFR2 from 7–9 GWs to 10–12
GWs in both sexes compared to testes at 7–9 GWs. The expression
of OCT4 was significantly (P < 0.05) higher in the ovaries compared
to testes at both time intervals in the first trimester and there was
a significantly (P < 0.05) higher POU5F1 (OCT4) expression in testes
at 10–12 GWs compared to 7–9 GWs. This most likely reflects the
greater number of germ cells in fetal ovaries compared to fetal testes
(Bendsen et al., 2003, 2006) as well as a high proliferation rate at
the investigated developmental time point. The expression of NR2F2
was similar between testis and ovary samples at 7–9 GWs, but with
a significant increase (P < 0.001 and P < 0.05) in expression level
in testes at 10–12 GWs, when compared to testes at 7–9 GWs.
Moreover, the expression of NR2F2 was significantly (P < 0.05) higher
in ovaries at 10–12 GWs compared to 7–9 GWs. Expression levels
of SOX9 and CYP17A1 were significantly higher in 7–9 GW testes
compared to ovaries at 7–9 GWs (P < 0.05) and at 10–12 GWs
(P < 0.01 and P < 0.05, respectively). Moreover, there was a significant
increase (P < 0.001 and P < 0.01) in the expression levels of both
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Figure 1 Expression of FGF9, FGFR2 and fetal cell lineage markers in human fetal gonads. (A) Transcriptional expression of FGF9,
FGFR2, OCT4 (POU5F1), NR2F2, SOX9 and CYP17A1 in ovary and testis samples from the first trimester. Gene expression is normalized to RPS29 and
expressed relative to testis samples from 7–9 GWs, which were set to a value of 1. Values represent mean ± SEM and for each age group n = 6–8.
Significant difference compared to fetal testes 7–9 GWs, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. GW: gestational week. (B) Immunohistochemical staining
of FGF9, OCT4 (fetal germ cell marker), SOX9 (Sertoli cell marker, in fetal testis sample only), FOXL2 (granulosa cell marker, in fetal ovary sample
only) and COUP-TFII (interstitial cell marker) in human ovary and testis samples from 10 GWs. Counterstaining with Mayer’s haematoxylin, scale bar
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Figure 2 Effects of manipulating FGF signalling on proliferation and apoptosis in human fetal gonads.Effects on expression of markers
of proliferation and apoptosis following FGF9 (25 ng/ml) and SU5402 (10 μM) treatment for 14 days in ex vivo cultures of fetal (A) ovaries and
(B) testes. Immunohistochemical staining for the proliferation marker BrdU (which was added to culture media for the last 6 h of culture), and the
apoptosis markers cleaved PARP (cPARP) was examined. Counterstaining with Mayer’s haematoxylin, scale bar corresponds to 50 μm. (C) Percentage
of proliferating (BrdU+) germ cells after 14 days of culture in fetal ovaries and testes. Values represent mean ± SEM, with n = 10 (vehicle, ovaries),
n = 7 (FGF9, ovaries), n = 6 (SU5402, ovaries), n = 9 (vehicle, testes), n = 8 (FGF9, testes), n = 7 (SU5402, testes). Significant difference compared to
vehicle controls, ∗P < 0.05, ∗∗∗P < 0.001. (D) Percentage of apoptotic (cPARP+) germ cells after 14 days of culture in fetal ovaries and testes. Values
represent mean ± SEM, with n = 10 (vehicle, ovaries), n = 8 (FGF9, ovaries), n = 6 (SU5402, ovaries), n = 10 (vehicle, testes), n = 8 (FGF9, testes),
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Figure 3 Effects of manipulating FGF signalling on the expression of germ cell markers in human fetal ovaries. (A) Expression
pattern of germ cell markers OCT4 (oogonia), MAGE-A4 (subpopulation of oogonia transitioning into oocytes) and γ H2AX (meiotic germ cells) in
fetal ovary samples treated with FGF9 (25 ng/ml) and SU5402 (10 μM) for 14 days in ex vivo culture. Arrows indicate MAGE-A4+ cells. Counterstaining
with Mayer’s haematoxylin, scale bar corresponds to 50 μm. (B) Quantification of germ cells determined as the number of OCT4+ gonocytes per
mm2. Values represent mean ± SEM, with n = 14 (vehicle), n = 7 (FGF9) and n = 6 (SU5402). Significant difference compared to vehicle controls,
∗∗∗P < 0.001. (C) Quantification of meiotic germ cells determined as the number of γ H2AX+ germ cells per mm2. Values represent mean ± SEM,
with n = 12 (vehicle), n = 7 (FGF9) and n = 6 (SU5402). Significant difference compared to vehicle controls, ∗P < 0.05, ∗∗P < 0.01.
7–9 GWs, respectively. Finally, expression of SOX9 and CYP17A1 was
significantly higher (P < 0.001) in 10–12 GW testes compared to
10–12 GW ovaries. At the protein level, FGF9 was expressed in
germ cells in both fetal testes and ovaries as well as in Sertoli cells,
a sub-population of interstitial cells in testes and a sub-population of
somatic cells in ovaries (Fig. 1B, Supplementary Fig. S1A). However,
this expression pattern differs to some extent compared to a previous
study that examined FGF9 expression in human fetal gonads using a
different antibody (Frydman et al., 2017). Other cell lineage markers:
OCT4 (germ cells), SOX9 (Sertoli cells), FOXL2 (granulosa cells) and

























Effects on proliferation and apoptosis
following manipulation of FGF signalling
in human fetal gonad cultures
Next, the effect of manipulating FGF signalling in ex vivo cultures of
human fetal testes and ovaries was examined by treatment with either
recombinant FGF9 (25 ng/ml) or the FGFR-inhibitor SU5402 (10 μM)
for 2 weeks. Effects on proliferation were examined based on BrdU
incorporation, and apoptosis was detected based on expression of
cleaved PARP (cPARP). In the ovaries, it was evident that treatment
with the SU5402 inhibitor resulted in fewer BrdU+ cells, while no
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Figure 4 Effects of manipulating FGF signalling on expression of somatic cell markers in human fetal ovaries. Expression pattern
of somatic cell markers COUP-TFII (interstitial cells), FOXL2 (granulosa cells) and WNT4 (primarily in granulosa cells) in fetal ovary samples treated
with FGF9 (25 ng/ml) and SU5402 (10 μM) for 14 days in ex vivo culture. Counterstaining with Mayer’s haematoxylin, scale bar corresponds to
50 μm.
only few cPARP+ cells were found in the ovary cultures regardless of
treatment (Fig. 2A). In the testis cultures, treatment with SU5402 also
reduced the number of BrdU+ cells, and again no apparent difference
was observed between FGF9-treated samples and vehicle controls
(Fig. 2B). Importantly, in vehicle control and FGF9-stimulated ovary and
testis samples, both germ cells and somatic cells continued to prolif-
erate during the culture period, indicating that the culture approach
supports continued cell proliferation. Few cPARP+ cells were detected
in testis cultures after 14 days of culture regardless of treatment,
although it appeared that more cPARP+ cells were present in SU5402
treated testis samples and overall more cPARP+ cells were found in
fetal ovary compared to testis samples. The observation that treatment
with SU5402 reduced germ cell proliferation was confirmed after quan-
tification of the percentage of BrdU+ germ cells, which was significantly
reduced (P < 0.05 and P < 0.001) in ovaries and testes, respectively
(Fig. 2C). No effect of FGF9 stimulation on proliferation of germ
cells was found in either fetal ovaries or testes (Fig. 2C). Additionally,
quantification of the percentage of cPARP+ germ cells demonstrated
that treatment with SU5402 significantly increased (P < 0.001) the
number of apoptotic cells in both ovaries and testes (Fig. 2D). In
contrast, stimulation of FGF9 signalling did not affect the percentage






















































Effects on expression of cell lineage markers
in human fetal ovary cultures following
manipulation of FGF signalling
Stimulation of FGF9 signalling did not affect the overall expression
pattern of OCT4 in oogonia compared to vehicle controls, but after
treatment with the SU5402 inhibitor, expression of OCT4 was almost
completely abolished (Fig. 3A). This observation was confirmed after
quantification of OCT4+ cells per area, where a significantly lower
(1456 vs. 28, P < 0.001) number of oogonia (OCT4+) were found
following SU5402 treatment (Fig. 3B). To distinguish whether this
effect was due to specific downregulation of pluripotency factors,
differentiation or loss of the oogonia population, additional markers
were examined. Examination of the pluripotency markers AP2γ
and NANOG resulted in a similar finding as for OCT4 with almost
no positive cells detected (data not shown). Therefore, expression
of MAGE-A4 (marker for differentiating oogonia) was examined
to establish whether FGF9 and/or SU5402 treatment promoted
differentiation. However, few MAGE-A4+ cells were detected, with
no difference between the vehicle controls and samples treated with
FGF9 or SU5402 (Fig. 3A). To establish whether manipulation of
FGF signalling affected initiation of meiosis in germ cells, expression
of the meiosis marker γ H2AX was examined. γ H2AX+ cells were
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but since γ H2AX marks double-strand breaks, the positive cells may
be undergoing apoptosis and therefore morphological assessment
is required to ensure that γ H2AX+ cells are indeed meiotic.
Quantification of meiotic cells demonstrated that treatment with
FGF9 and SU5402 both resulted in a significantly lower (P < 0.05 and
P < 0.01, respectively) number of γ H2AX+ cells per area (Fig. 3C).
However, the reduced number of γ H2AX+ germ cells in SU5402-
treated ovaries is most likely a consequence of the very low number
of germ cells remaining in these samples and not SU5402-mediated
inhibition of meiotic entry. To assess the effects of SU5402 treatment
on the somatic niche in fetal ovaries, somatic cell lineage markers,
COUP-TFII (stromal/interstitial cells), FOXL2 (granulosa cells) and
WNT4 (granulosa cells), were examined by IHC in fetal ovary
samples following treatment with FGF9 and SU5402. However, no
apparent difference in the expression pattern of any of these somatic
cell lineage markers was observed compared to vehicle controls
(Fig. 4).
Effects on expression of cell lineage markers
in human fetal testis cultures following
manipulation of FGF signalling
Stimulation of FGF9 signalling did not appear to affect the expression
of germ cell markers OCT4 and MAGE-A4, Sertoli cell markers SOX9
and AMH or the interstitial cell marker COUP-TFII (Fig. 5A). In con-
trast, treatment with SU5402 resulted in pronounced morphological
alterations in the fetal testis tissue, with smaller and more rounded
seminiferous cords. The cords contained Sertoli cells that appeared
larger and were located closer to the basement membrane, while the
interstitial area was increased compared to vehicle-treated samples
(Fig. 5A). Moreover, in accordance with the results from the fetal
ovary cultures, treatment with SU5402 in fetal testes resulted in almost
complete loss of OCT4+ gonocytes (Fig. 5A). To examine whether
this lack of OCT4+ germ cells was a consequence of premature differ-
entiation to pre-spermatogonia (MAGE-A4+), specific downregulation
of OCT4 expression or loss of the germ cell population, additional
germ cell markers were included in the analysis. Since almost no pre-
spermatogonia (MAGE-A4+) cells were detected (Fig. 5A) and no
AP2γ + or LIN28+ cells were found (data not shown), it appeared
that the majority of the gonocyte population in fetal testis was lost
as a consequence of SU5402 treatment. This was also evident after
quantification of OCT4+ cells per area, which was significantly reduced
(224 vs. 14 OCT4+ per mm2, P < 0.05) in SU5402-treated fetal testis
samples (Fig. 5B). The SU5402 treatment also reduced the expression
of somatic cell lineage markers AMH (Sertoli cells) and COUP-TFII
(interstitial cells) (Fig. 5A), but did not promote trans-differentiation of
Sertoli cells towards granulosa-like cells based on the lack of FOXL2
expression (data not shown). In contrast, treatment with SU5402 did
not affect the expression of SOX9 in Sertoli cells, but the number
of Sertoli cells appeared reduced (Fig. 5A). This was confirmed by
quantifying the number of SOX9+ cells per area, which was significantly
lower (2503 vs. 1561, P < 0.05) following treatment with SU5402
compared to vehicle controls (Fig. 5C). Interestingly, this quantification
also demonstrated that stimulation of FGF9 signalling had the opposite
effect and significantly increased (2503 vs. 3872, P < 0.05) the number
of SOX9+ cells per area compared to vehicle controls, indicating





























































































































Effects of manipulating FGF signalling on
expression of Leydig cell markers and
steroidogenesis in fetal testis cultures
Stimulation of FGF9 signalling did not result in any apparent effects
on the expression of the Leydig cell markers CYP11A1, CYP17A1
and 3β-HSD (Fig. 6). In contrast, treatment with SU5402 resulted
in an apparent increase in expression of CYP11A1 and CYP17A1,
but did not appear to affect 3β-HSD expression (Fig. 6). To deter-
mine whether fetal Leydig cell function was altered following FGF9
and SU5402 treatment, steroidogenesis was evaluated by analysis of
media collected from ex vivo cultures throughout the experimental
period. FGF9 treatment resulted in significantly higher levels of 17-
hydroxyprogesterone (ratio 1 vs. 1.5, P < 0.05) and progesterone
(ratio 1 vs. 2.6, P < 0.05) (Fig. 7A), while SU5402 treatment did not
result in alterations in steroidogenesis, except for a significantly higher
level of cortisone (ratio 1 vs. 2.4, P < 0.05) (Fig. 7B).
Discussion
During recent years, much progress has been made in the under-
standing of molecular mechanisms and signalling pathways underlying
gonadal sex differentiation in mice. However, only a few studies have
investigated these in human development mainly due to the difficulty
in obtaining fetal tissue. In the present study, we investigated the
involvement of FGF9, and signalling through FGFR, in human fetal
gonad development, taking advantage of our established ex vivo culture
model (Jørgensen et al., 2015, 2018). We demonstrated that following
our attempt to inhibit FGFR signalling by treatment with SU5402, a
severely reduced number of germ cells in both human fetal testes and
ovaries was observed. In addition, inhibition of FGF signalling by use of
SU5402 also affected the somatic niche in human fetal testes, including
effects on testicular morphology and expression pattern of cell lineage
markers, while stimulation of FGF9 signalling promoted Sertoli cell
proliferation in testes and inhibited meiotic entry in ovaries. These
findings demonstrate the potential importance of the FGF9 signalling
pathway in human fetal gonad development.
Inhibition of FGFR signalling by SU5402 treatment severely impaired
the germ cell population with almost complete loss of OCT4+ cells
in gonads of both sexes, which was explained by both reduced germ
cell proliferation and increased apoptosis. Despite the increase in
percentage of apoptotic cells after 2 weeks in culture, it is likely that the
majority of germ cells in SU5402-treated samples were lost at an earlier
time point during the experimental period. Similar results were recently
demonstrated following simultaneous inhibition of Nodal and Activin
signalling in human fetal testes using the same experimental approach
(Jørgensen et al., 2018). In contrast, stimulation of FGF9 signalling in
human fetal gonads did not affect proliferation or apoptosis of the
germ cells. These findings are partly in accordance with previous studies
in Fgf9 KO mice, in which germ cell loss (by apoptosis) occurred in
fetal testes, but not in ovaries (DiNapoli et al., 2006). The observed
reduction in germ cell number, resulting from both increased apoptosis
and reduced proliferation following treatment with SU5402 in human
fetal ovaries is in line with the observed expression of FGF9 in germ
cells of human fetal gonads of both sexes, which was reported in
the present study as well as in previous studies (Ostrer et al., 2007;
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Figure 5 Effects of manipulating FGF signalling on expression of germ cell and somatic cell markers in human fetal testes.
(A) Expression pattern of germ cell markers OCT4 (gonocytes), MAGE-A4 (pre-spermatogonia) and somatic cell markers SOX9 (Sertoli cells), AMH
(Sertoli cells) and COUP-TFII (interstitial cells) in fetal testis samples treated with FGF9 (25 ng/ml) and SU5402 (10 μM) for 14 days in ex vivo culture.
Arrows indicate MAGE-A4+ cells. Counterstaining with Mayer’s haematoxylin, scale bar corresponds to 50 μm. (B) Quantification of germ cells
determined as the number of OCT4+ gonocytes per mm2. Values represent mean ± SEM, with n = 12 (vehicle), n = 8 (FGF9) and n = 7 (SU5402).
Significant difference compared to vehicle controls, ∗P < 0.05. (C) Quantification of Sertoli cells determined as the number of SOX9+ cells per mm2.
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Figure 6 Effects of manipulating FGF signalling on expression of Leydig cell markers in human fetal testes. Expression pattern of
fetal Leydig cell markers CYP11A1, CYP17A1 and 3β-HSD in fetal testis samples treated with FGF9 (25 ng/ml) and SU5402 (10 μM) for 14 days in ex
vivo culture. Counterstaining with Mayer’s haematoxylin, scale bar corresponds to 50 μm.
in germ cell maintenance in both human fetal testes and ovaries. In
contrast, expression of Fgf9/FGF9 in mice becomes testis-specific
upon initiation of gonadal sex differentiation (Colvin et al., 2001; Nef
et al., 2005; Kim et al., 2006). Stimulation of FGF9 signalling in human
fetal ovary cultures reduced the number of meiotic germ cells, which
is in accordance with a previous study (Frydman et al., 2017). This was
despite the use of a lower concentration of FGF9 (25 ng/ml) in the
present study compared to 1 μM FGF9 used previously (Frydman et al.
2017). However, Frydman et al. (2017) also reported that inhibition
of FGFR signalling (using a different early generation FGFR inhibitor,
PD173074, 1 μM) increased the number of meiotic germ cells in fetal
ovaries, which is in contrast to the present study where a reduced
number of meiotic cells was found after FGFR inhibition (SU5402,
10 μM). We consider the result of the present study to most likely
be a consequence of the overall loss of the germ cell population
and not a direct effect on initiation of meiosis. In fetal mouse ovary
cultures treatment with FGF9 resulted in repressed WNT4 expression
(Kim et al., 2006; Jameson et al., 2012) as well as upregulation of
pluripotency markers Oct4 and Sox2 and male-fate markers Nanos2
and Dnmt3l (Bowles et al., 2010). In contrast to the studies in mice, the
present study showed no effects on the number of OCT4+ cells or the
expression of somatic cell lineage markers WNT4, FOXL2 and COUP-
TFII after treatment with recombinant FGF9 or SU5402 in human fetal
ovary cultures.
In contrast to the ovaries, manipulation of FGF signalling in fetal

























































resulted in an increased number of Sertoli cells, which is in line
with previous studies in mice where FGF9 was shown to promote
proliferation (and differentiation) of Sertoli cells (Schmahl et al., 2004).
In accordance, the present study demonstrated that treatment with
SU5402 reduced the number of SOX9+ cells and also the presence of
proliferating Sertoli cells appeared to be reduced. These findings are
also in line with mouse studies where a reduced Sertoli cell number
was reported in Fgf9 KO mice, which also had smaller testes and
failed to develop seminiferous cords (Colvin et al., 2001; Schmahl
et al., 2004). Interestingly, we observed that the human testis tissue
fragments treated with SU5402 were clearly smaller compared to
both vehicle controls and other treatments. Even though it was not
possible to quantify the growth of the testis fragments in culture
in the present study, this observation could indicate involvement
of FGF9 signalling in mediating fetal testis growth also in humans.
In the present study, treatment with SU5402 did not affect the
formation or maintenance of seminiferous cords in human fetal testis
cultures, despite our previous studies demonstrating pronounced
effects on this end-point following inhibition of Nodal signalling
(Jørgensen et al., 2018) and following treatment with exogenous
retinoic acid (Jørgensen et al., 2015). Despite the presence of intact
seminiferous cords in SU5402-treated human fetal testes in the present
study, some effects were observed, including a rounder shape of
tubules with Sertoli cells appearing larger and located closer to
the basement membrane. Moreover, in human fetal testis cultures
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Figure 7 Effects of manipulating FGF signalling on steroido-
genesis in human fetal testes. Quantification of steroid hormone
metabolites produced in ex vivo cultures of fetal testis tissue and
secreted to the media droplets. Medium was collected every 48 h
throughout the 14 days culture period and was pooled for each
individual tissue piece. Androgens were measured by LC-MS/MS and
are shown as ratios compared to corresponding vehicle controls. (A)
Effect of FGF9 (25 ng/ml) treatment for 14 days in ex vivo culture.
Values represent mean ± SEM, with n = 16 (vehicle) and n = 16
(FGF9). Significant difference compared to vehicle control, ∗P < 0.05.
(B) Effect of SU5402 (10 μM) treatment for 14 days in ex vivo
culture. Values represent mean ± SEM, with n = 12 (vehicle) and
n = 12 (SU5402). Significant difference compared to vehicle control,
∗P < 0.05.
of AMH, which is in accordance with results from Fgfr2 KO mice
(Bagheri-Fam et al., 2015) as well as a patient with 46,XY monosomy





























































































































patient had reduced serum AMH levels, but the testosterone levels
were within the normal range (Tosur et al., 2015) and in the present
study, we found that treatment with SU5402 had no overall effect
on steroidogenesis, including the testosterone levels. This was to
some extent in contrast to the apparent increase in the expression of
steroidogenic enzymes CYP11A1 and CYP17A1 observed following
SU5402 treatment. The stimulation of FGF9 signalling resulted in
increased levels of 17-hydroxyprogesterone and progesterone in
media from testis cultures. This finding could indicate increased
3β-HSD enzyme activity, despite the apparent lack of increased 3β-
HSD protein expression compared to vehicle controls. In fetal mouse
urogenital ridge cultures, treatment with SU5402 (5 μM) resulted
in downregulation of male-promoting genes Nanos2 and Dnmt3l
(Bowles et al., 2010), which is in line with the present study where
downregulation of AMH and COUP-TFII expression was observed
in addition to the reduced number of SOX9+ cells. In the study by
Wu et al. (2013), treatment of testis cultures with SU5402 (40 μM)
resulted in upregulation of the female-promoting genes Wnt4, Foxl2,
Fst and Bmp2 (Wu et al., 2013). This is in contrast to the present study
where expression of FOXL2 could not be detected in fetal testes
treated with a lower dose of SU5402 (10 μM).
The FGFR-inhibitor (SU5402) selected for the present study has
previously been used to investigate the effects of inhibiting FGF9
signalling in fetal mouse testis and ovary cultures, using concentrations
ranging from 5 μM (Bowles et al., 2010; Spiller et al., 2012), 20 μM
(Tian-Zhong et al., 2016) up to 40 μM (Wu et al., 2013). In a recent
study comparing the ability of different FGFR tyrosine kinase (TK)
inhibitors to rescue FGF2-mediated inhibition of rat chondrocyte pro-
liferation, the lowest concentration of SU5402 needed to rescue this
phenotype was determined to be 10 μM (Gudernova et al., 2016),
which is also in keeping with a previous study using 10 μM SU5402
to induce human embryonic stem cell differentiation (Vallier et al.,
2005). This suggests that the dose of 10 μM used in the present study
is appropriate. However, the study by Gudernova et al. (2016) high-
lighted that all investigated FGFR inhibitors, including SU5402, targeted
the activity of all FGFRs and exhibited significant off-target activity,
which was especially pronounced for SU5402. Therefore, caution is
warranted in the interpretation of results following SU5402-mediated
FGFR-inhibition, since it is not possible to exclude that some of the
observed effects are the results of simultaneous inhibition of other
tyrosine kinases. Additionally, since the expression pattern of FGF9 in
human fetal gonads to some extent differs between the IHC and IF
stainings in the present study as well as when compared to previous
studies (Ostrer et al., 2007; Frydman et al., 2017), this is a limitation of
our study. We detected expression of FGF9 in germ cells in fetal testes
and ovaries, which is in accordance with a previous study reporting
expression in male germ cells using the same antibody (Ostrer et al.,
2007). Furthermore, single cell RNA sequencing (scRNA-seq) data also
indicated FGF9 expression in germ cells from both sexes (Li et al., 2017,
data shown in Supplementary Fig. 1B and C). In contrast, Frydman
et al. (2017) did not report expression of FGF9 in germ cells in
human fetal ovaries or testes using a different antibody. In the present
study, expression of FGF9 was consistently detected in germ cells
following IHC and IF, while IF also resulted in staining in several other
cell types. Whether the reported expression of FGF9 in germ cells
in human fetal gonads results from non-specific staining of the used
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Figure 8 Proposed involvement of FGF9/FGFR2 signalling in human fetal gonad development. A model illustrating the interaction
between key factors involved in early gonad development. SRY upregulates SOX9 in Sertoli cells of the developing testes resulting in the self-promoting
expression of SOX9, which is followed by expression of additional testis-promoting factors, including FGF9. FGF9 signals through FGFR2 to inhibit the
pro-ovarian factor WNT4 (and the RSPO1/β-catenin pathway). The present study confirmed the FGF9-mediated inhibition of meiotic entry in female
germ cells previously demonstrated in human fetal ovaries (Frydman et al., 2017). Additionally, this study suggests the involvement of FGF9/FGFR2 in
the expression of SOX9 in human fetal testes. Finally, the present study suggests involvement of FGF9/FGFR2 signalling in supporting germ cell survival
in both sexes.1 Reviewed in Rotgers et al., 2018.
pattern of FGF9 in the present study should be interpreted with
caution.
In conclusion, the present study demonstrated that pharmaceutical
inhibition of FGFR signalling in human fetal gonads, by treatment
with SU5402, had pronounced effects on survival of the germ cell
population, resulting in a severely reduced number of gonocytes and
oogonia in fetal testes and ovaries, respectively. In addition, inhibi-
tion of FGFR signalling affected the somatic niche in human fetal
testes, with effects on testicular morphology and expression pattern
of cell lineage markers. Stimulation of FGF9 signalling resulted in a
higher number of Sertoli cells in testes, while in ovaries we observed
FGF9-mediated inhibition of meiotic entry. The findings of this study
are summarized in Figure 8 in the context of previous mouse and
human studies. Together, our findings indicate that FGF9 signalling
may be involved in the signalling cascade directing human gonadal
differentiation and suggest that dysregulation of this pathway may
have consequences for both testicular and ovarian development in
humans.
Supplementary data
Supplementary data are available at Human Reproduction online.
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